Results from the US Clinical Trial of PNEUMOSTEM for Treating Lung Disease is Published in International Journal2019/05/13STEM CELL THERAPEUTIC
MEDIPOST, ends phase I and II clinical trials with PNEUMOSTEM, the effective treatment of BPD for preterm infants2019/01/08STEM CELL THERAPEUTIC
MEDIPOST Completes Phase 1 and 2 Clinical Trials with its Lung Disease Treatment Drug ‘PNEUMOSTEM’ in US2016/06/30STEM CELL THERAPEUTIC
MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease2016/05/03STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in Canada for its ‘PNEUMOSTEM’ Used to Treat Lung Diseases2016/03/10STEM CELL THERAPEUTIC
‘PNEUMOSTEM’ selected as the ‘Newly developed and promising medical technology’ by National evidence based healthcare collaborating agency2015/11/02STEM CELL THERAPEUTIC
MEDIPOST announced extension plans in US ’2015 Stem Cell Meeting on the Mesa’2015/10/07STEM CELL THERAPEUTIC
Lung disease medicine, ‘PNEUMOSTEM’ was designated as ‘Orphan Drug’ in Europe2015/07/06STEM CELL THERAPEUTIC
The only Korean company invited to North American Rare Medicine conference2015/04/24STEM CELL THERAPEUTIC
Administration of lung disease medicine ‘PNEUMOSTEM’ in clinical trial completed2015/04/15STEM CELL THERAPEUTIC